bluuebunny/crossref_metadata_2025 huggingface dataset:
931-P: Optimal Treatment Intensification for Glycemic Control in Patients with T2D on Two Oral Agents: Real-World Comparison of GLP-1, OADs, and Insulin
Authors: DESOUZA CYRUS , KIRK ANDREAS ROSS , MANGLA KAMAL K. , WOLDEN MICHAEL L. , LINGVAY ILDIKO
Published: June 2020

Introduction: Health care providers have many options for achieving glycemic control in individuals with T2D requiring treatment intensification. In this analysis from the PATHWAY study we address the question of optimal treatment choice, comparing intensification with additional oral antidiabetic drug (OAD), glucagon-like peptide-1 (GLP-1) analogs or insulin in individuals on 2 OADs.

Methods: Electronic medical records and claims data were from IBM MarketScan Explorys Claims-EMR (index period: 3/1/13-10/31/18). Inclusion required ≥1 claim for 2 different OADs in the 180 days pre-index, ≥1 claim for another OAD/GLP-1/insulin (day 0; index date), ≥1 HbA1c and weight measurement 180 days post-index (+/− 90 days), and ≥1 HbA1c and weight measurement close to index date (baseline). Cohorts for GLP-1s vs. OADs and vs. insulin were propensity score matched pairwise by baseline variables and exact matched by HbA1c category (Figure).

Results: Cohorts were well balanced across all baseline characteristics after matching. GLP-1 cohorts were significantly more likely to reach target HbA1c <7% and HbA1c <7% with no weight gain than either OADs or insulin (Figure).

Conclusions: Our results support clinical decision-making at treatment intensification, indicating that individuals on 2 OADs are more likely to achieve targets with GLP-1s than with further OAD or insulin.

Disclosure

C. Desouza: Consultant; Self; AstraZeneca, Bayer AG, Novo Nordisk A/S. A. Kirk: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. K.K. Mangla: Employee; Self; Novo Nordisk A/S. M.L. Wolden: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. I. Lingvay: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Janssen Pharmaceuticals, Inc., MannKind Corporation, Novo Nordisk A/S, Sanofi, TARGET PharmaSolutions, Valeritas, Inc. Other Relationship; Self; Novo Nordisk A/S.

Funding

Novo Nordisk A/S
941-P: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Semaglutide in Healthy Chinese Subjects
Authors: SHI AIXIN , XIE PANPAN , NIELSEN LASSE L. , SKJOETH TRINE V. , HE XUEMEI , HAUGAARD SINE P.
Published: June 2020

Semaglutide is a glucagon-like peptide-1 analogue (GLP-1) approved for once-weekly (OW) subcutaneous treatment of type 2 diabetes (Ozempic®). This randomised, double-blind, placebo-controlled, 13-week trial assessed the pharmacokinetics, safety and tolerability of OW semaglutide in healthy male and female Chinese subjects. A total of 36 subjects were randomised to 0.5 mg (n=12) or 1.0 mg (n=12) OW semaglutide, or corresponding volumes of placebo (n=12). The primary endpoint was steady-state semaglutide exposure (AUC0 168h [area under the curve over a dosing interval]). Semaglutide exposure at steady state (see Figure) was consistent with dose-proportionality. Treatment ratios (1.0 mg/0.5 mg) were: AUC0-168h: 1.99, and Cmax: 1.94. Accumulation was consistent with the half-life (∼1 week). In this trial, treatment with OW semaglutide was well tolerated, consistent with the GLP-1 class. The PK profile in Chinese subjects was consistent with previous trials. The most common adverse events were gastrointestinal events. NCT03288740.

Disclosure

A. Shi: None. P. Xie: None. L.L. Nielsen: None. T.V. Skjoeth: Employee; Self; Novo Nordisk A/S. X. He: None. S.P. Haugaard: Employee; Self; Novo Nordisk A/S.

Funding

Novo Nordisk A/S
947-P: Semaglutide Added to Treatment or Changed from Other GLP-1 Receptor Agonist in Type 2 Diabetes: A Study to Evaluate Real-World Effectiveness
Authors: FERRER-GARCÍA JUAN CARLOS , GALERA RAQUEL ALBALAT , ARRIBAS LUIS , TORRENS MERCEDES TOLOSA , LORENTE ANDREA SÁNCHEZ , PORTILLA ANA J. , ARTERO ANA , SÁNCHEZ-JUAN CARLOS
Published: June 2020

Objective: To evaluate real-world clinical outcomes of semaglutide on glycemic control and weight as an add-on to treatment or changed-on from other GLP-1 in patients with T2D who initiate treatment.

Patients and Methods: To better understand the effectiveness of semaglutide on clinical outcomes in a real-world setting, this retrospective cohort study included eligible patients were at least 18 years old with uncontrolled T2D (HbA1c 6.5-11%) receiving stable therapy that initiated subcutaneous semaglutide 0.5 or 1.0 mg once weekly added to their therapy or after a change from other GLP-1. Primary endpoint was change from baseline in glycated Hb (HbA1c) and confirmatory secondary endpoint was change from baseline in body weight, both at week 24. Semaglutide was initiated as part of their diabetes therapy based in clinical practice.

Results: in this study, were included 147 patients had a mean age of 60.3 ± 10.1 years, T2D duration of 14.0 ± 7.4 years, and baseline A1C of 8.3 ± 1.34%. Seventy-five were naïve in treatment with GLP-1 and seventy-four received previously another GLP-1 (liraglutide 1.8 mg daily or dulaglutide 1.5 mg once weekly). At 6 months follow-up, 145 patients who remained on-treatment showed an A1C reduction of 1.2 ± 1.15% (p<0.05), A1C lowering was seen in both groups: a reduction de 1.8±1.8% (p < 0.05) in patients that received GLP for first time and 0.6± 1.0%(p< 0.05) in group prior use of GLP-1. Mean weight reduction was 5.1 ± 4.6 kg (p < 0.001) in the group initiated GLP-1 for first time and 2.1±4.0 kg (p<0.01) in group that changed from another GLP-1. Four patients presented gastrointestinal adverse events to retire the treatment, all of them in the group that never had been treated with GLP-1.

Conclusion: In this real-world study, patients initiating semaglutide had significant reductions in HbA1c and weight. The effect was reached whether patients received GLP-1 for the first time or if a change had been made from another GLP-1.

Disclosure

J. Ferrer-García: None. R. Albalat Galera: None. L. Arribas: None. M. Tolosa Torrens: None. A. Sánchez Lorente: None. A.J. Portilla: None. A. Artero: None. C. Sánchez-Juan: None.
95-OR: Plasma miRNAs Levels at First Trimester of Pregnancy Predict Insulin Sensitivity Estimated at the Second Trimester of Pregnancy
Authors: LÉGARÉ CÉCILIA , DESGAGNÉ VÉRONIQUE , WHITE FRÉDÉRIQUE , SCOTT MICHELLE S. , PERRON PATRICE , HIVERT MARIE-FRANCE , GUÉRIN RENÉE , BOUCHARD LUIGI
Published: June 2020

Background: Gestational diabetes mellitus (GDM) is the most common pregnancy complication with a prevalence of 14% worldwide and has important consequences on both the mother and her child. GDM results from imbalance between insulin secretion capacity response and decreasing insulin sensitivity in pregnancy. MicroRNAs (miRNAs) are small (19-24nt) single-stranded RNA molecules involved in post-transcriptional regulation through binding to targeted mRNAs. MiRNAs are thought to regulate many physiological processes including glucose homeostasis.

Objective: Identify plasmatic miRNAs at the first trimester of pregnancy that predict insulin sensitivity (IS; as estimated with the Matsuda index) assessed between the 24th and the 28thweek of pregnancy. Methods: miRNAs were quantified by next generation sequencing in 443 plasma samples from the Gen3G birth-cohort. DESeq2 package was applied to identify miRNAs associated with IS. Glmnet package was used to compute lasso regression and find the minimum number of miRNAs predicting IS.

Results: On average, participants were 28.43 ± 4.3 (18-47) years old and had a BMI of 26.1 ± 6.1 (16.6-54.1) kg/m2 at first trimester and had a Matsuda index of 8.41 ± 4.9 (0.77-37.53) at second trimester. A total of 106 miRNAs were associated with IS (p-adjusted for false discovery rate <0.1) when analyses were corrected for gestational age at blood collection, with 37 of them remaining significant after further correction for maternal age and BMI measured at first trimester. A lasso regression selected 27 of these miRNAs along with maternal age and BMI and overall explained 32% of the variability of IS at second trimester.

Conclusion: miRNAs quantified at first trimester of pregnancy are associated with and predictive of maternal IS estimated at second trimester. These miRNAs are likely involved in the pathophysiology of GDM and provide novel promising biomarkers for predicting glucose metabolism dysregulation in pregnancy.

Disclosure

C. Légaré: None. V. Desgagné: None. F. White: None. M.S. Scott: None. P. Perron: None. M. Hivert: None. R. Guérin: None. L. Bouchard: None.

Funding

IRSC (IGH-155183)
958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis
Authors: CLEGG LINDSAY E. , DER AART ANNEMARIE VAN , PENLAND ROBERT C. , BOULTON DAVID W. , SJÖSTRÖM C. DAVID , MENTZ ROBERT J. , HOLMAN RURY R. , HEERSPINK HIDDO L.
Published: June 2020

GLP-1 RA effects on major kidney outcome in unselected T2D patients at high cardiovascular (CV) risk are modest or neutral. However, GLP-1 RA may provide renal benefit in those at high risk of worsening kidney disease. We examined once-weekly exenatide (EQW) effects on eGFR slope and UACR change, as a function of baseline UACR, in a subset of EXSCEL participants. Of 14752 EXSCEL participants, eGFR slope was assessed in those with baseline UACR and ≥1 post-baseline eGFR (n=3503 [23.7%]) via mixed model repeated measures (MMRM) analysis (median follow-up 3.3 years). UACR percent change from baseline to first post-baseline measurement (median time 8.9 months) was assessed in those with baseline and ≥1 follow-up UACR (n=2828 [19.2%]) via ANCOVA of log-transformed UACR, with baseline UACR as a covariate. Participants with baseline UACR measurements were generally similar to the overall EXSCEL population, and balanced across treatment arms. EQW improved eGFR slope in those with baseline UACR>100mg/g and UACR>200mg/g, but not at lower UACR thresholds. No difference in EQW effect on eGFR was observed as a function of baseline eGFR, CV disease history, RAAS inhibitor use, or SBP. UACR improvement was similar across UACR categories. This EXSCEL post-hoc analysis suggests that EQW reduces UACR, with improvement in eGFR slope specifically in participants with elevated baseline UACR.

Disclosure

L.E. Clegg: Employee; Self; AstraZeneca. A. van der Aart: None. R.C. Penland: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. D.W. Boulton: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca, Bristol-Myers Squibb. C. Sjöström: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. R.J. Mentz: Consultant; Self; Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Sanofi. Research Support; Self; GlaxoSmithKline plc. R.R. Holman: Advisory Panel; Self; Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S. Research Support; Self; AstraZeneca, Bayer AG, Merck Sharp & Dohme Corp. H.L. Heerspink: Consultant; Self; AbbVie Inc., AstraZeneca, Boehringer Ingelheim International GmbH, CSL Behring, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Mundipharma International, Retrophin, Inc.

Funding

AstraZeneca
96-OR: Integrative Omics Analysis Revealed That the Metabolic Changes in Placental Cells from Gestational Diabetes Mellitus Are Reflected in Their Secreted Exosomes
Authors: NAIR SOUMYALEKSHMI , JAYABALAN NANTHINI , SCHOLZ-ROMERO KATHERIN , GUANZON DOMINIC , LAI ANDREW , MCINTYRE DAVID , LAPPAS MARTHA , SALOMON CARLOS
Published: June 2020

Exosomes are membrane-bound extracellular vesicles secreted from a range of cells including human placental cells and contain specific cargo such as proteins, and miRNAs. The aim of this study was to determine the miRNA and protein profile in primary human trophoblast (PTH) and their secreted exosomes obtained from placentae from women with normal glucose tolerant (NGT) and gestational diabetes mellitus (GDM). Using quantitative proteomic analysis, 34 proteins were significantly different in PTH from GDM compared with NGT. Similarly, a specific set of proteins were significantly different in PTH exosomes from GDM compared with NGT. An Illumina TrueSeq Small RNA kit was used to construct a small RNA library from PTH and exosomes. We identified a set of miRNAs (miR-181, miR-151, miR-10a, miR-744, miR-1468 and miR-4507) which their expression varied in a consistent pattern in PTH and their secreted exosomes in GDM compared with NGT. Interestingly, a specific set of proteins and miRNAs were selectively enriched with exosomes and compared with their PTH of origin in NGT and GDM indicating a specific packaging of proteins and miRNAs into exosomes. We used Ingenuity Pathway Analysis (IPA) analysis to identify miRNA-gene interactions using the miRNA and proteomic data and created a network link with the down- and up-regulated pairs of miRNA-proteins. IPA core analysis showed that the top canonical pathway associated with these miRNAs were PI3/AKT signalling and glucose metabolism/insulin resistance, respectively. We proposed that exosomes are “fingerprints” of the releasing cells and their metabolic status. Exosomes released from placenta can modify the phenotype of target cells, inducing metabolic changes in GDM to contribute to changes in insulin sensitivity during pregnancy.

Disclosure

S. Nair: None. N. Jayabalan: None. D. Guanzon: None. A. Lai: None. D. McIntyre: Other Relationship; Self; Novo Nordisk A/S. M. Lappas: None. C. Salomon: None.

Funding

Diabetes Australia; Fondo Nacional de Desarrollo Científico y Tecnológico (1170809)
961-P: Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Sitagliptin as Add-On to Metformin in Subjects with Type 2 Diabetes (SUSTAIN China MRCT): A 30-Week Double-Blind, Phase 3a, Randomised Trial
Authors: JI LINONG , XIAOLIN DONG , ELIASCHEWITZ FREDDY , LI YIMING , LI YUFENG , LIM SOO , LIU MING , ZU NING , RASMUSSEN SOEREN , SKJOETH TRINE V. , YUAN GUOYUE , HUANG YU-YAO
Published: June 2020

A total of 868 subjects of which 70% were Chinese and 13% Korean were randomised to once-weekly subcutaneous semaglutide 0.5 mg (n=288), 1.0 mg (n=290) or sitagliptin 100 mg (n=290) in a multiregional clinical trial. Both doses of semaglutide were superior to sitagliptin in reducing HbA1c (primary endpoint, Figure 1) and body weight (Table 1) after 30 weeks of treatment. The odds for achieving target HbA1c, weight loss of ≥5% or ≥10% and a composite endpoint were all significantly higher with both semaglutide doses compared to sitagliptin (Table 1). The safety profile of semaglutide was consistent with the previously established profile. Consistent efficacy and safety findings were seen in the Chinese population.

Disclosure

L. Ji: None. D. Xiaolin: None. F. Eliaschewitz: Advisory Panel; Self; AstraZeneca, Novo Nordisk A/S, Sanofi-Aventis. Research Support; Self; Bayer AG, GlaxoSmithKline plc., Novo Nordisk A/S, Sanofi-Aventis. Speaker’s Bureau; Self; Eli Lilly and Company. Y. Li: None. Y. Li: None. S. Lim: None. M. Liu: None. N. Zu: Employee; Self; Novo Nordisk A/S. S. Rasmussen: Employee; Self; Novo Nordisk A/S. T.V. Skjoeth: Employee; Self; Novo Nordisk A/S. G. Yuan: None. Y. Huang: None.

Funding

Novo Nordisk A/S
964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program
Authors: DUNGAN KATHLEEN M. , HERTZ CHRISTIN L. , MELLBIN LINDA , NIELSEN MORTEN ABILDLUND , SØRRIG RASMUS , WOO VINCENT C. , VILSBØLL TINA
Published: June 2020

The PIONEER phase 3 program investigated glycemic response and other efficacy endpoints in patients (pts) with type 2 diabetes randomized to the glucagon-like peptide-1 analog oral semaglutide (sema; 3, 7 or 14 mg once daily), placebo (pbo) or an active comparator (empagliflozin [empa] 25 mg, sitagliptin [sita] 100 mg or liraglutide [lira] 1.8 mg once daily). This post-hoc analysis of the PIONEER 1-5 and 8 trials evaluated the response of any reduction in HbA1c (%) and/or body weight (%), and a clinically relevant composite endpoint of HbA1c reduction ≥1% and body weight loss ≥5%, with oral sema 14 mg vs. comparators at the end of treatment (26-78 weeks). Across trials, any reduction in HbA1c was observed in higher proportions of pts with oral sema (89-95%) than with pbo (51-64%) or active comparators (82-88%). A simultaneous reduction in both HbA1c and body weight was seen in 72-86% of pts treated with oral sema (Figure). The composite of HbA1c reduction ≥1% and body weight loss ≥5% was achieved by 27-41% of pts with oral sema, 1-8% of pts with pbo, 11% with sita 100 mg, 18% with lira 1.8 mg, and 20% with empa 25 mg. Within each trial, the odds of achieving HbA1c reduction of ≥1% and body weight loss of ≥5% with oral sema 14 mg were significantly greater vs. all comparators (p<0.0001). These results demonstrate that oral sema 14 mg was more effective vs. comparators for providing any HbA1c reduction, or both an HbA1c reduction ≥1% and body weight loss ≥5%.

Disclosure

K.M. Dungan: Advisory Panel; Self; Eli Lilly and Company, Elsevier. Research Support; Self; Novo Nordisk Inc., Sanofi-Aventis. Speaker’s Bureau; Self; Nova Biomedical. Other Relationship; Self; UpToDate, Vizient Inc. C.L. Hertz: Employee; Self; Novo Nordisk A/S. L. Mellbin: Advisory Panel; Self; Amgen, AstraZeneca, Novo Nordisk A/S, Sanofi-Aventis. Consultant; Self; AstraZeneca, Bayer AG, Novo Nordisk A/S. Research Support; Self; Bayer AG. Speaker’s Bureau; Self; Novo Nordisk A/S. Other Relationship; Self; Novo Nordisk Foundation. M. Abildlund Nielsen: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. R. Sørrig: Employee; Self; Novo Nordisk A/S. V.C. Woo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi-Aventis. T. Vilsbøll: Advisory Panel; Self; AstraZeneca, Mundipharma International, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Medscape, Merck Sharp & Dohme Corp., Sanofi.

Funding

Novo Nordisk A/S
977-P: Alleviating Carbohydrate Counting with a FiASP-and-Pramlintide Artificial Pancreas: A Randomized Pilot Study
Authors: TSOUKAS MICHAEL , PALISAITIS EMILIE , RUTKOWSKI JOANNA , VON OETTINGEN JULIA E. , LEGAULT LAURENT , YALE JEAN-FRANÇOIS , HAIDAR AHMAD
Published: June 2020

Objective: The aim of this pilot study was to assess if a FiASP-and-pramlintide artificial pancreas (AP) could alleviate the need for CHO counting by using a simple meal announcement system (pressing a button, no CHO counting) without degrading glycemic control.

Methods: We conducted a 24-hour inpatient, randomized, crossover, non-inferiority, pilot study to compare (i) FiASP AP with full CHO counting (FCC) and CHO-matched boluses with (ii) FiASP-and-pramlintide AP with simple meal announcement (SMA). Pramlintide and FiASP were delivered in a basal-bolus manner using a fixed ratio (1U: 10µg).

Results: Seven participants (age 26.2±16, HbA1c 8.4±0.8%) were included in the analysis. The time in range (3.9-10 mmol/L) was 85.7% (IQR: [72-93]) in the FCC arm and 87.3% [75-95] in the SMA arm (p=0.21). Time spent >10mmol/L did not differ between interventions (FCC: 11.4% [0.9-22], SMA: 10.1% [3.1-25], p=0.38). Time <3.9mmol/L was lower in the SMA arm (2.1% vs. 4.1%, p=0.02). One participant experienced persistent GI symptoms in the SMA arm.

Conclusions: The FiASP-and-pramlintide SMA system has the potential of reducing the burden of CHO counting without degrading glucose control. Outpatient studies are warranted.

Disclosure

M. Tsoukas: Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk Inc. Speaker’s Bureau; Self; Boehringer Ingelheim (Canada) Ltd., Janssen Scientific Affairs, LLC. E. Palisaitis: None. J. Rutkowski: None. J.E. von Oettingen: None. L. Legault: Advisory Panel; Self; Dexcom, Inc., Lilly Diabetes. Research Support; Self; AstraZeneca K.K., Merck & Co., Inc., Sanofi-Aventis. Other Relationship; Self; Lilly Diabetes. J. Yale: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Board Member; Self; Diagnos. Research Support; Self; Bayer Inc., Novo Nordisk A/S, Sanofi. Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Novo Nordisk A/S, Sanofi. A. Haidar: Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc., Eli Lilly and Company.

Funding

JDRF (2-SRA-2018-654-M-B)
978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
Authors: FORLENZA GREGORY P. , BUCKINGHAM BRUCE A. , SHERR JENNIFER , WADWA R. PAUL , GALDERISI ALFONSO , EKHLASPOUR LAYA , BERGET CARI , HSU LIANA , ZGORSKI MELINDA , LEE JOON BOK , OCONNOR JASON B. , DUMAIS BONNIE , VIENNEAU TODD , HUYETT LAUREN M. , LY TRANG T.
Published: June 2020

Customization of glucose targets in hybrid closed-loop (HCL) systems is important to enable tailored glucose management and safe onboarding across a wide range of users. The safety and performance of the Omnipod HCL personalized model predictive control (MPC) algorithm were assessed with a lower target of 110mg/dL for the first time in those aged 12-85y with type 1 diabetes (T1D) and A1C<10.0% using an investigational device.

A 96-h HCL study was conducted in a supervised free-living hotel setting with challenges including 2 missed meal boluses, high fat dinner, and daily exercise. All participants used a 120mg/dL target for 48h, with either a day/night target of 150/110 mg/dL (n=10) or a constant 110mg/dL target (n=10) for the remaining 48h.

Participants (n=20) were (mean±SD): age 17.9±4.4y, T1D duration 9.0±5.4y, and A1C 7.6±0.9%. Despite 2 missed meal boluses (23-162g CHO), percent time from 70-180mg/dL was 76.1±14.9% and 72.9±9.2% with targets of 110 and 120mg/dL respectively (Table). Percent time <70mg/dL was low: 2.3±2.1% and 1.9±2.5% at the respective targets.

The Omnipod personalized MPC algorithm performed well and was safe in adults and adolescents with T1D when tested at a target of 110mg/dL, even when stress-tested under challenging conditions. This algorithm is being evaluated in an at-home pivotal study with targets 110-150mg/dL.

Disclosure

G.P. Forlenza: Advisory Panel; Self; Medtronic. Consultant; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. Research Support; Self; Abbott, Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Medtronic. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. J. Sherr: Advisory Panel; Self; Bigfoot Biomedical, Cecelia Health. Consultant; Self; Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Medtronic, Sanofi, T1D Exchange. R. Wadwa: Advisory Panel; Self; Eli Lilly and Company, Medtronic. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, MannKind Corporation, Medtronic, Novo Nordisk Inc., Tandem Diabetes Care. A. Galderisi: None. L. Ekhlaspour: None. C. Berget: None. L. Hsu: Stock/Shareholder; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. M. Zgorski: None. J. Lee: Employee; Self; Insulet Corporation. J.B. OConnor: None. B. Dumais: Employee; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. L.M. Huyett: Employee; Self; Insulet Corporation. T.T. Ly: Employee; Self; Insulet Corporation.

Funding

Insulet Corporation
981-P: Postprandial Hyperglycemia following Insulin Suspensions by the Artificial Pancreas: Implications for Bolus Calculators
Authors: MAJOR SANDRINE , FATHI ANAS EL , PALISAITIS EMILIE , KEARNEY ROBERT E. , VON OETTINGEN JULIA E. , LEGAULT LAURENT , HAIDAR AHMAD
Published: June 2020

Objective: Conventional bolus calculators apply negative prandial insulin corrections when pre-meal glucose levels are low. The present study examined the need for this negative correction with the artificial pancreas (AP).

Methods: Data were retrospectively analysed from a study conducted in a camp for children with type 1 diabetes. Meal boluses with negative corrections (n=98) of 47 participants (between 8-22 years old) using the McGill AP for 11 days were examined. The duration of insulin suspension before each meal and the insulin-on-board (IOB) at mealtime were calculated. The effects of these factors on postprandial hyperglycemia were analysed.

Results: The rate of postprandial hyperglycemia was 28% (18/65) for meals preceded by basal insulin suspensions <70 minutes, and 52% (17/33) for meals preceded by suspensions ≥70 minutes (p=0.02). The rate of postprandial hyperglycemia following suspensions ≥70 minutes compared to <70 minutes was significantly higher only if there was no IOB (64% [9/14] vs. 29% [13/45]; p=0.01). Meal size and total daily insulin dose did not influence these results.

Conclusion: Negative corrections with meal boluses may not be necessary following long insulin suspensions in the absence of IOB.

Disclosure

S. Major: None. A. El Fathi: None. E. Palisaitis: None. R.E. Kearney: None. J.E. von Oettingen: None. L. Legault: Advisory Panel; Self; Dexcom, Inc., Lilly Diabetes. Research Support; Self; AstraZeneca K.K., Merck & Co., Inc., Sanofi-Aventis. Other Relationship; Self; Lilly Diabetes. A. Haidar: Consultant; Self; Eli Lilly and Company. Research Support; Self; Dexcom, Inc., Eli Lilly and Company.

Funding

Canadian Institutes of Health Research (356406)
985-P: Insulin Excipient Removal Is Counterbalanced by Insulin Fibril Formation
Authors: LEWIS BRIANNE , MULKA ADAM , KESSERWAN CHAFICA , KREUTZER DON , KLUEH ULRIKE
Published: June 2020

Objective: Insulin infusion pump sets are only FDA approved for 3 days as device failure often ensues from an inflammatory response driven by insulin excipients. However, removal of excipients can result in insulin fibril formation, which is more toxic than excipients alone. Our objective was to determine excipient and fibril toxicity and optimize the parameters of insulin excipient removal.

Methods: A modified murine air pouch model with an inline filter removed excipients prior to insulin infusion/injection. Protein analysis by circular dichroism (CD) measured protein stability upon excipient removal. A separate analysis determined cytotoxicity for insulin fibrils in cell and tissue. These studies were also extended into a porcine model.

Results: Excipient removal significantly reduced the inflammatory response in vivo. However, this resulted in a loss of insulin oligomeric state. In vitro and in vivo studies demonstrated toxicity of excipients (in vitro and in vivo) and fibrils (in vivo) (Figures 1A-D).

Conclusions: These studies demonstrate that insulin excipients result in cell and tissue toxicity. Complete removal of these excipients alters protein stability. Since inflammation is minimized with removal of excipients, current studies are directed at optimizing the infusion parameters and excipient concentrations.

Disclosure

B. Lewis: None. A. Mulka: None. C. Kesserwan: None. D. Kreutzer: Other Relationship; Self; Abbott Laboratories, cell and molecualar tissue enginnering (cmte). U. Klueh: Research Support; Self; Abbott. Other Relationship; Self; Cell and Molecular Tissue Engineering, LLC.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust
99-OR: An Inflection Point (IP) of C-Peptide (C-P) Decline during Progression to Type 1 Diabetes (T1D)
Authors: ISMAIL HEBA M. , SKYLER JAY S. , SOSENKO JAY , PALMER JERRY P. , EVANS-MOLINA CARMELLA , DIMEGLIO LINDA , REDONDO MARIA J. , STECK ANDREA , ATKINSON MARK A. , HEROLD KEVAN C. , NATHAN BRANDON M.
Published: June 2020

Evidence suggests the presence of an IP for accelerated β-cell loss during progression to T1D. Importantly, identification of an IP could guide subject selection for prevention trials. We used a 2-dimensional grid of area under the curve (AUC) glucose vs. AUC C-P to detect a C-P IP among Diabetes Prevention Trial-Type 1 (DPT-1; n=54) and TrialNet (TN; n=59) autoantibody positive (Ab+) participants. All analyzed were required to have OGTTs at baseline and every 6 months, then 2.0, 1.5, 1.0 and 0.5 yrs before diagnosis. In DPT-1, an IP was evident 1.5 yrs from diagnosis (Figure) (AUC C-P change from baseline to 1.5 yrs: 0.22±0.60 ng/ml, p=0.006; from 1.5 to 0.5 yrs: -0.42±1.23 ng/ml, p=0.026). In TN, a 1.5 yr IP was also evident (from baseline to 1.5 yrs: 0.18±0.95 ng/ml, p=0.184; from 1.5 to 0.5 yrs: -0.53±1.57 ng/ml, p=0.015), despite an older TN cohort (14.9±12.1 vs. 10.5±6.8 yrs, p=0.023) with higher AUC C-P (5.0±1.9 vs. 3.3±1.6 ng/ml, p<0.001). There was no IP in non-progressors.

In summary, an IP occurred 1.5 yrs before diagnosis when C-P began to decline as glucose continued to increase in DPT-1 and TN, suggesting that a 1.5 yr IP of C-P decline is consistent among Ab+ populations. These findings emphasize the importance of identifying at risk individuals as potential participants in prevention trials prior to the IP, when the loss of insulin secretion becomes more severe.

Disclosure

H.M. Ismail: None. J.S. Skyler: Advisory Panel; Self; Abvance Therapeutics, ADOCIA, Avotres, Boehringer Ingelheim Pharmaceuticals, Inc., Dance Biopharm Holdings, Inc., Immunomolecular Therapeutics, Intrexon, Oramed Pharmaceuticals, Orgenesis Inc., Sanofi, Tolerion, Inc., Viacyte, Inc. Board Member; Self; Applied Therapeutics, Dexcom, Inc., Intarcia Therapeutics. Consultant; Self; Novo Nordisk A/S. Research Support; Self; Tolerion, Inc. Stock/Shareholder; Self; Applied Therapeutics, Dexcom, Inc., Intarcia Therapeutics. J. Sosenko: None. J.P. Palmer: None. C. Evans-Molina: Consultant; Self; Bristol-Myers Squibb. L. DiMeglio: None. M.J. Redondo: None. A. Steck: None. M.A. Atkinson: None. K.C. Herold: Consultant; Self; Provention Bio, Inc. B.M. Nathan: None.

Funding

National Institutes of Health
994-P: Clinical Study of a New Extended Wear Infusion Set
Authors: ILANY JACOB , COHEN OHAD , KONVALINA NOA , ZHANG GINA , CHATTARAJ SARNATH
Published: June 2020

Objective: Current real-time continuous glucose monitoring (CGM) sensors are approved for 7-14 days of wear, whereas insulin infusion sets are indicated for 2-3 days of wear. Development of a closed-loop control system with the same duration of wear for its CGM and insulin infusion consumables necessitates an infusion set with greater longevity. This study assessed the safety and performance of a newly designed Extended Wear Infusion Set (EWIS) for up to 7 days.

Method: A single-center feasibility study targeted the recruitment of 26 adult subjects (between 22 and 75 years of age) This was a 1-center, prospective, open label one arm study, with each subject being asked to wear 4 trial devices until the infusion set failed or 7-day use was reached.

Result: There were twenty-one participants of whom 20 completed the study, resulting in 82 insertions and 78 wear counts. At 7 days of wear, the overall failure rate for the EWIS was 19.5%, which was comparable to that after 3-day use for a 3-day infusion set (∼23%) (MiniMed™ Quick-set), as previously reported. (Patel et al. Diabetes Technol Ther. 2014; 16:15-19). Over time, EWIS use for 7 days did not significantly increase hyperglycemia (mean SG value Day 3: 150 ± 56 mg/dL; Day 6: 160 ± 50 mg/dL; target < 250 mg/dL) or total daily insulin requirements (TDI at Day 1: 41±17 U/Day; Day 3: 40±17 U/Day; Day 7: 43 ±20 U/Day) There were no events of infusion set blockage or diabetic ketoacidosis during the study.

Conclusion: The performance of the EWIS across 7 days of use was equivalent to the performance reported for a 3-day infusion set during 3 days of use. Safety outcomes during EWIS use were acceptable for the intended subcutaneous insulin infusion by an external pump for 7 days.

Disclosure

J. Ilany: Research Support; Self; Medtronic. O. Cohen: Employee; Self; Medtronic. N. Konvalina: None. G. Zhang: None. S. Chattaraj: Employee; Self; Medtronic.

Funding

Medtronic
NKG2D signaling within the pancreatic islets reduces NOD diabetes and increases protective central memory CD8+ T cell numbers
Authors: Admin Ada , Trembath Andrew P. , Krausz Kelsey L. , Sharma Neekun , Gerling Ivan C. , Mathews Clayton E. , Markiewicz Mary A.
Published: June 2020

NKG2D is implicated in autoimmune diabetes. However, the role of this receptor
in diabetes pathogenesis is unclear owing to conflicting results with studies
involving global inhibition of NKG2D signaling. We found that NKG2D and its
ligands are present in human pancreata, with expression of NKG2D and its
ligands increased in the islets of patients with type 1 diabetes. To directly
assess the role of NKG2D in the pancreas, we generated NOD mice that express an
NKG2D ligand in b-islet cells. Diabetes
was reduced in these mice. The reduction corresponded with a decrease in the effector
to central memory CD8+ T cell ratio. Further, NKG2D signaling during in vitro activation of both
mouse and human CD8+ T cells resulted in an increased number of central
memory CD8+ T cells
and diabetes protection by central memory CD8+ T cells in
vivo. Taken together, these studies demonstrate that there is a protective role
for central memory CD8+ T cells in autoimmune diabetes and that this
protection is enhanced with NKG2D signaling.
These findings stress the
importance of anatomical location when determining the role NKG2D signaling
plays, as well as when developing therapeutic strategies targeting this
pathway, in type 1 diabetes development.
PENERJEMAHAN DAN VALIDASI KUESIONER “EDUCATIONAL NEEDS OF CAREGIVERS INSTRUMENT” KE DALAM BAHASA INDONESIA PADA CAREGIVERS PASIEN GAGAL JANTUNG
Authors: Rahayu Sri , Chen Hsing-Mei
Published: June 2020

Sampai sejauh ini belum tersedia instrumen atau kuesioner untuk mengetahui kebutuhan pendidikan caregivers pasien gagal jantung di Indonesia. Tujuan dari penelitian ini adalah untuk menerjemahkan dan memvalidasi kuesioner versi Bahasa Inggris “Educational Needs of Caregivers Instrument” ke dalam versi Bahasa Indonesia. Proses penerjemahan dan adaptasi dilakukan berdasarkan lima tahapan pedoman penerjemahan dan adaptasi dari World Health Organization. Hasil penelitian menunjukkan bahwa terdapat 5 istilah berbeda antara dua budaya: “talk” vs “discuss”, “to know the expected course of the disease process”, “to receive information about how to go about making lifestyle changes”, “to feel as if others have my welfare in mind”, “to have help with finansial concerns”. Enam ahli dalam bidang kardiovaskuler dilibatkan dalam penilaian validasi konten instrumen. Hasilnya menunjukkan bahwa indeks validasi konten adalah 0.93 untuk relevansi, 0.91 untuk keakuratan, 0.83 untuk kejelasan, dan 0.84 untuk kemudahan dipahami. Pada akhirnya, tercipta kuesioner versi Bahasa Indonesia yang disebut “Kuesioner Kebutuhan Pendidikan Caregivers” dan kuesioner ini dinyatakan valid.
PENGARUH PUPUK HAYATI DAN BAHAN ORGANIK TERHADAP POPULASI DAN BIOMASSA CACING TANAH PADA PERTANAMAN BAWANG MERAH (Allium ascalonicum L) DI KECAMATAN MERBAU MARATAM KABUPATEN LAMPUNG SELATAN
Authors: Arofi Annove Kurnia , Yusnaini Sri , Hendarto Kus , Arif Mas Achmad Syamsul
Published: June 2020

This study aimed to determine the effect of biofertilizer, organic matter and the interaction between biofertilizer and organic matter on population, biomass of earthworm and shallot production. This experiment was conducted in Merbau Mataram, South Lampung Regency on September – December 2017, designed by using Randomize Block Design (RBD) with two factors, i.e. : Biofertilizer application consists of biofertilizer and non biofertilizer and organic matter application consists of chicken manure, cow manure, oyster mushroom baglog and straw compost. Analysis of variance (anova) was carried out using a significance level of 0,05 after verifying the additivity (Tukey’s test) and homogeneity of variance (Bartlett’s test) of the data. When a significant effect was revealed in the anova, the mean separations among treatments were obtained by least significant difference (LSD 0.05).  The results showed that application of biofertilizer (Bio max grow) increased earthworm population in 37 days after planting at 10 – 20 cm depth and 70 days after planting at 0 – 10 and 10 – 20 cm depth, biofertilizer application also affected earthworm biomass and shallot production in 70 days after planting. Oyster mushroom application gave the best effect compared to the other organic matter on population and biomass of earthworm and shallot production.
PENGARUH PENAMBAHAN PUPUK MIKRO DAN BEBERAPA GENOTIPE SORGUM (Sorghum bicolor (L.) Moench) TERHADAP INTENSITAS PENYAKIT ANTRAKNOSA (Colletotrichum sp.) DI LAHAN PETANI TANJUNG BINTANG LAMPUNG SELATAN
Authors: Muli Farastika Unjunan , Efri Efri , Hadi Muhammad Syamsoel , Suharjo Radix
Published: June 2020

One of the diseases that often found in sorghum plants is anthracnose disease caused by Colletotrichum sp. The purposed of this study was to determine the effect of adding micro fertilizer and the use of several sorghum genotypes on the intensity of anthracnose disease. The study was conducted in Sukanegara, Tanjung Bintang, South Lampung in April 2017 - February 2018 and at the Laboratory of Plant Diseases and Pests, Faculty of Agriculture, University of Lampung. The treatments were arranged using a randomized block design in a split plot design (3 times replications), the main plot was micro nutrients (with micro addition and without micro addition) and 15 subgroups of sorghum genotypes (Numbu, Samurai 1, GH3, UPCA, GH4, P / I WHP, GH6, Super 2, GH13, P / F 51-93-C, Super 1, GH5, Mandau, GH7, and Talaga Bodas). The results showed that the addition of "ZincMicro" micro fertilizers to sorghum plants did not affect the intensity of anthracnose disease, however there were differences in the intensity of anthracnose diseases between sorghum genotypes. Numbu Genotype, GH 3, and GH 13 were relatively more resistant to anthracnose disease than the other genotypes.
EFIKASI HERBISIDA PARAKUAT UNTUK PENGENDALIAN GULMA PADA BUDIDAYA KELAPA SAWIT (Elaeis guineensis Jacq) TANAMAN BELUM MENGHASILKAN
Authors: Sidik Jatmiko Umar , Sembodo Dad Resiworo Jekti , Evizal Rusdi , Pujisiswanto Hidayat
Published: June 2020

Good plantation management is important to increase the productivity of immature oil palm plants, one of which is chemical weed control. This study aims to (1) determine the dosage of paraquat herbicide which is effective in controlling weeds in the area of immature oil palm plantations, (2) find out the differences in the composition of weed species on immature oil palm plates after application of the paraquat herbicide, (3) find out the phytotoxicity of paraquat herbicides in immature oil palm plants after the application of the paraquat dichloride herbicide. This research was carried out in the farmers' oil palm plantation in Jontor Village, Gayabaru District , Central Lampung Regency and Weed Laboratory of the Faculty of Agriculture, University of Lampung from November 2017 to February 2018. This research used a Randomized Block Design (RBD) with 4 replications and 6 treatments consisting dose of paraquat dichloride herbicide of 375g / ha, 500 g / ha, 625 g / ha, 750 g / ha, and mechanical weeding and without weed control (control). Homogeneity of the various data was tested by the Bartlett test, data additivity was tested by the Tukey test and the difference in the mean was tested with the Least Significant Difference (LSD) test at α 5 level. The result of the study showed that : (1) the herbicide paraquat dichloride dose of 375-750 g / ha effectively control weeds in total, weed leaf width of up to 8 week after application, weed grasses and weeds puzzle to 4 week after application, (2) the herbicide paraquat dichloride dose of 375-750 g / ha is effective in controlling Praxelis clematidea weeds up to 8 week after application, weed Ottochloa nodosa and Asystasia gangetica up to 4 week after application, (3) paraquate dichloride dosage levels 375-750 g / ha resulting in differences in weed composition at 4, 8 and 12 week after application , (4) dosages of 375 - 750 g / ha parakuat dichloride herbicides applied to dishes not poisoning immature oil palm plants.
Case Research of Personology of Filipino Children in Conflict with the Law (CICL)
Authors: Dominguez Jemerson Naceno
Published: June 2020

In the Philippines, afar from the usual attachment, a child sometimes leads to offend out of survival necessity that leads to total separation from their family, this explains a phenomenon of conflict to the law. Aiming to describe the profile and personology of CICL in Bahay Kalinga; and its correlates. Case research was used in analyzing violations, family structure and personology among 20 participants. In-house CICL’s profile depicted: 15 years and 9 months as average age; substantial number of boys committed offences than girls; commonly falls below poverty rate; majority stop schooling; all own a dysfunctional family; and affirmed 4-5 family members. Regarding personology, mostly verified an average self-concept, majority pointed out having realistic self-image, and beyond median represented low self-esteem. Descriptions and measures of their profile and personology could determine the risk of being CICL. The patterns of personology were focused through the information of their extracted statements. Personology traits and types play a vital role in the concepts described by Filipino CICL. Thus, there were seven themes that build up the collection of personology as precedents of traits and patterns. Replicate the study to establish Philippine norm of cases associated with conflict of the law.
O debate sobre a participação no planejamento urbano no Brasil contemporâneo 1 | The discussion about participation in urban planning in contemporary Brazil
Authors: Goulart Jefferson Oliveira
Published: June 2020

O processo de democratização do Brasil produziu inovações que envolveram o protagonismo dos movimentos sociais e depois a institucionaliza­ção das formas participativas. Assim perdeu-se a perspectiva da posição polar “representação x participação” porque esta passou a ocupar lugar de destaque no governo representativo. No âmbito do planejamento urbano, o Movimento Nacional pela Reforma Urbana teve ação destacada ao inscrever um capítulo inédito na Constituição, depois regu­lamentado no Estatuto da Cidade, sob o emblema da “gestão democrática da cidade”. Os fatores de êxito do planejamento participativo indicam três variáveis complementares a serem avaliadas: capa­cidade organizativa da sociedade civil; conduta do governo de turno; e a forma como a legislação trata a participação. A análise do caso brasileiro revela a multiplicação formal de instrumentos participati­vos no campo do planejamento (planos diretores, conferências setoriais, audiências e consultas públicas, conselhos nos três níveis de governo etc.), no entanto, a observação empírica e a literatura revelam escassos avanços na efetiva capacidade de democratizar decisões.
In media barbaria, ille ego romanus vates: etnografia e autoridade nos Tristia de Ovídio
Authors: Ugartemendía Cecilia Marcela
Published: June 2020

Durante seu exílio em Tomos, Ovídio escuda-se na ideia de declínio poético e linguístico, causado pela hostilidade do entorno. A adversidade do lugar em que deve cumprir a relegatio é o argumento para justificar a queda na qualidade de sua produção poética. Neste trabalho, propomos analisar aspectos da descrição etnográfica e geográfica apresentada por Ovídio nos Tristia 3.10 e 5.7, com o objetivo de adicionar mais elementos à longa tradição de estudos dedicados a demonstrar que a ideia de declínio é mais um artificio retórico na construção da persona relegata. Para tanto, a discussão será delimitada pela construção do eu poético como autoridade no tratamento do sofrimento do exílio. Em primeiro lugar, são analisados trechos de Tr. 3.10, dedicados à descrição etnográfica e geográfica da Cítia, na qual se destaca o manejo da sintaxe mimética. Em seguida, oferecemos diferentes observações sobre a já muito comentada intertextualidade entre esta epístola e a descrição da Cítia oferecida por Vírgilio em Geórgicas 3.349-83, destacando que as diferenças entre uma e outra descrição atendem à construção da autoridade de Ovídio como exilado, inclusive ao se arrogar o “direito de corrigir” o poeta anterior. Em segundo lugar, buscamos comprovar que, em Tr. 5.7, Ovídio relegatus continua a se construir como autoridade, reivindicando, no meio de sua aparente barbarização, seu lugar como grande Romanus vates.
Cícero, Do Orador 2.216-290
Authors: Scatolin Adriano , Miotti Charlene Martins
Published: June 2020

Tradução do excurso sobre o riso no diálogo Do orador (2.216-290), de Cícero, apresentado pelo personagem Gaio Júlio César Estrabão Vopisco.
Sobre a Natureza, de Parmênides de Eleia
Authors: Barbieri Pedro
Published: June 2020

Ofereço uma tradução poética da obra Sobre a natureza, de Parmênides.
Alexandre, O Grande, na Alexandra, de Lícofron
Authors: Rocha Roosevelt
Published: June 2020

Neste breve artigo farei um comentário detalhado dos versos 1435-45, da Alexandra, de Lícofron. Nesse poema, Cassandra, a filha do rei troiano Príamo e irmã de Páris Alexandre, faz uma série de profecias sobre o futuro de Troia e dos gregos que estão prestes a conquistar a cidade no momento em que ela profetiza. Dentre essas previsões, ela menciona rapidamente Alexandre, o Grande, que fará dormir os conflitos entre Ocidente e Oriente. O que pretendo fazer aqui é apresentar uma análise detalhada dos onze versos nos quais o conquistador macedônio é mencionado: com que metáforas e com que imagens ele é retratado, a que linhagens ele pertence e a que lugares ele é associado.
Antiguidades românticas: onde se encontram os guerreiros antigos e selvagens
Authors: Oliveira Maria Edith Maroca de Avelar Rivelli de , Ipiranga Júnior Pedro
Published: June 2020

As mudanças mentais ocorridas no século XVII e a resultante separação entre os antigos e os modernos, nos séculos seguintes (XVIII e XIX) acarretaram transformações semânticas substanciais na relação com a herança clássica. Entre essas mudanças (bem demonstradas pelo culto romântico da originalidade), destacam-se as novas categorias e formas em que a experiência humana foi modelada, cujos modelos teóricos e narrativos propunham um novo gênero: a história nacional. A certeza de superação dos antigos foi também responsável pelo plural de antiguidades nacionais. Surpreendentemente, porém, essas novas narrativas revelar-se-iam em grande dívida para com a tradição clássica: principalmente, na formulação heroica dessas novas antiguidades.
Ligações perigosas? Alexandre e Aristóteles nos filmes de Modi, Rossen e Stone
Authors: Coelho Maria Cecília de Miranda Nogueira
Published: June 2020

Considerando a controversa imagem de Alexandre, o Grande, que recebemos por meio dos textos da Antiguidade, não é de se espantar que sua representação no cinema seja também muito variada e complexa. O mais antigo e menos conhecido dos filmes sobre ele é Sikandar (1941, Índia), de Sohrab Modi, obra interessante não apenas porque a personagem é vista pela perspectiva dos conquistados, mas pela presença muito significativa de Aristóteles e Roxana. Posteriormente, sua história foi levada à tela nos filmes Alexandre o Grande (1956), de Robert Rossen, e Alexandre (2004), de Oliver Stone. Meu objetivo, neste artigo, é o de analisar aspectos desses três filmes, comparativamente, com atenção às imagens de Aristóteles, a fim de compreender como a presença do filósofo é retratada e alinhada à construção da imagem do rei macedônio.